Search
Raxibacumab
go.drugbank.com/drugs/DB08902ApprovedInvestigationalRaxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons. Raxibacumab is produced by recombinant DNA tech...
Picosulfuric acid
go.drugbank.com/drugs/DB09268ApprovedInvestigationalThe combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years.[A33322]
DADLE
go.drugbank.com/drugs/DB08856ExperimentalIt can cause transient depression of mean arterial blood pressure and heart rate.
Copper usnate
go.drugbank.com/drugs/DB13830ExperimentalCategories: Genito Urinary System and Sex HormonesPudexacianinium
go.drugbank.com/drugs/DB19161InvestigationalPudexacianinium is under investigation in clinical trial NCT05754333 (A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery).
Synonyms: )-1,1-dimethyl-1h-benz(e)indolium ion, )ETHYLIDENE)-2-METHOXYCYCLOHEX-1-EN-1-YL)ETHEN-1-YLeptin
go.drugbank.com/drugs/DB05098InvestigationalAlthough leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin.
Bitolterol
go.drugbank.com/drugs/DB00901ApprovedWithdrawnBitolterol mesylate was used to treat bronchospasms in asthma and COPD. It is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.
Deslanoside
go.drugbank.com/drugs/DB01078ApprovedDeacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata.
Fluticasone
go.drugbank.com/drugs/DB13867ApprovedInvestigationalWithdrawnFluticasone is a synthetic glucocorticoid available as 2 esters, DB08906 and DB00588 [FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications [FDA Label]. DB00588 was ...
CNS-5161
go.drugbank.com/drugs/DB05824ExperimentalCNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.